Returning Value to Shareholders through Dividends, Strong Financial Results, and Regulatory Approvals - Research Report on Lilly, Illumina, Regeneron, Teva, and Vanda Pharmaceuticals Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, October 24, 2013 NEW YORK, October 24, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Eli Lilly & Co. (NYSE: LLY), Illumina, Inc. (NASDAQ: ILMN), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Eli Lilly & Co. Research Report On October 21, 2013, Eli Lilly & Co. (Lilly) announced that the Company's Board of Directors has approved a quarterly dividend for Q4 2013 of $0.49 per share on outstanding common stock. The Company said that the dividend is payable on December 10, 2013, to shareholders of record at the close of business on November 15, 2013. The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/977d_LLY] -- Illumina, Inc. Research Report On October 21, 2013, Illumina, Inc. (Illumina) announced its Q3 FY 2013 financial results (period ended September 29, 2013). The Company's total revenue increased 24.8% YoY to $356.8 million during the quarter. Net income was $31.4 million or $0.22 per diluted share in Q3 FY 2013, compared to net income of $29.7 million or $0.22 per diluted share in Q3 FY 2012. Commenting on the results, Illumina's President and CEO Jay Flatley, said, "These results highlight another quarter of solid operational execution and record financial performance. We continue to be pleased with the robust global trends demonstrated by our business and believe we are positioned to continue to deliver strong growth." The Company expects FY 2013 revenue growth of approximately 22% YoY. The Company also expects FY 2013 non-GAAP fully diluted EPS of $1.75 to $1.77, including the impact of the acquisitions of Verinata and Advanced Liquid Logic. The Full Research Report on Illumina, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3cf2_ILMN] -- Regeneron Pharmaceuticals Inc. Research Report On October 21, 2013, Regeneron Pharmaceuticals Inc. (Regeneron) announced topline results for EYLEA (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO). The Company revealed that in this trial, 53% of patients who received EYLEA 2 milligram (mg) every four weeks gained at least 15 letters in vision from baseline at week 24, the primary endpoint of the study, compared to 27% of patients who received laser, a standard-of-care treatment (p < 0.001). In addition, Regeneron said that patients who received EYLEA 2 mg every four weeks achieved a 17.0 letter mean improvement over baseline in best corrected visual acuity (BCVA) compared to a 6.9 letter mean improvement in patients who received laser (p <0.0001), which was a key secondary endpoint of the study. Regeneron said that it intends to submit a regulatory application for marketing approval for macular edema following BRVO in the US within the next several months. The Full Research Report on Regeneron Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8ea7_REGN] -- Teva Pharmaceutical Industries Ltd. Research Report On October 14, 2013, Teva Pharmaceutical Industries Ltd. (Teva) announced that the US Food and Drug Administration has approved the generic equivalent of TOBI (Tobramycin Inhalation Solution USP) in the United States. The Company said that under an agreement with Novartis on the product, it expects to launch the product in late November 2013. Teva added that marketed by Novartis, TOBI had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013. The Full Research Report on Teva Pharmaceutical Industries Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e3a3_TEVA] -- Vanda Pharmaceuticals Inc. Research Report On October 21, 2013, Vanda Pharmaceuticals Inc. (Vanda Pharmaceuticals) announced that the Company will release results for Q3 2013 on November 7, 2013, before the market opens. In addition, Vanda Pharmaceuticals will host a conference call at 10:00 a.m. ET on the same day, during which Vanda management will discuss the Company's financial results. In a release published on July 31, 2013, Vanda Pharmaceuticals had affirmed its full-year 2013 guidance. The Company expects full-year 2013 decrease in Cash to be between $45.0 million and $50.0 million and full-year total operating expenses to be between $57.0 million and $62.0 million. The Full Research Report on Vanda Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b5ad_VNDA] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Returning Value to Shareholders through Dividends, Strong Financial Results, and Regulatory Approvals - Research Report on
Press spacebar to pause and continue. Press esc to stop.